NeuroQ is not FDA approved. It is a dietary supplement, and the FDA does not approve dietary supplements before they are sold to the public. This is a common point of confusion, partly because a completely unrelated medical device called “NeuroQ 3.8” (a type of imaging scanner used in radiology) did receive FDA clearance in 2018. The brain health supplement sold under the NeuroQ brand has no such approval.
Why the FDA Doesn’t Approve Supplements
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), dietary supplements are legally classified as a category of food, not drugs. That distinction matters because it means supplements follow a completely different regulatory path. The FDA does not review or approve supplement formulas or their labeling before they hit store shelves. In fact, the FDA has no systematic way of even knowing when a new supplement enters the market or what it contains.
The responsibility falls on the manufacturer. Companies that make or sell dietary supplements are responsible for ensuring their products are safe and that any claims on the label are truthful and backed by evidence. Supplements are allowed to make “structure/function” claims, which describe how a product affects the body’s normal processes. Think phrases like “supports memory” or “promotes focus.” What they cannot do is claim to diagnose, treat, cure, or prevent any disease. If a supplement crosses that line, it becomes subject to regulation as a drug.
Any supplement making structure/function claims is required to include a disclaimer on the label stating that the FDA has not evaluated the claim and that the product is not intended to treat or prevent disease. You’ll find this disclaimer on every bottle of NeuroQ.
What’s in NeuroQ
The NeuroQ Memory & Focus formula contains a blend of plant-based ingredients: ginkgo biloba, phosphatidylserine, coffee fruit extract, turmeric, gotu kola, and propolis. The company does not prominently list the exact milligram dosages for each ingredient on its product page, which makes it harder to compare what you’re getting against the doses used in clinical research on those individual compounds.
Several of these ingredients do have research behind them when studied in isolation. Phosphatidylserine, for example, was tested in a six-month trial of 78 older adults with mild cognitive impairment. Those taking phosphatidylserine showed improvements in delayed verbal recall, a type of memory that tends to decline early in cognitive aging, while the placebo group stayed flat. Notably, the benefits appeared at both 100 mg and 300 mg daily doses, and were most pronounced in people who started with lower memory scores.
Ginkgo biloba and turmeric each have their own bodies of research suggesting modest cognitive benefits, though results across studies are inconsistent. The key question with any blended supplement is whether the doses of each ingredient are high enough to match what was used in positive trials. Without transparent dosing on the label, that’s difficult to verify.
The Clinical Study on NeuroQ’s Formula
NeuroQ does point to one published study that tested its actual formula rather than individual ingredients. This was a multi-center, open-label trial, meaning participants knew they were taking the supplement and there was no placebo group for comparison. Over 90 days, participants showed a 14% increase in overall neurocognitive index scores. Specific improvements included a 12% gain in executive function, 11% in cognitive flexibility, 10% in processing speed, and 7% in working memory.
Those numbers sound encouraging, but the study design limits what you can conclude from them. Without a placebo group, there’s no way to separate the supplement’s effect from the placebo response, practice effects from repeated testing, or the lifestyle changes participants were also making during the trial. Open-label studies are useful as early-stage exploration, but they don’t meet the standard of a randomized, double-blind, placebo-controlled trial, which is the type the FDA requires before approving a drug for cognitive claims.
How This Compares to FDA-Approved Options
FDA-approved drugs for cognitive conditions go through years of rigorous testing across multiple phases of clinical trials involving hundreds or thousands of participants. They must demonstrate both safety and efficacy against placebo in controlled settings. Prescription medications for conditions like Alzheimer’s disease have cleared this bar, meaning the FDA has independently verified their benefits outweigh their risks for a specific condition.
Supplements like NeuroQ operate in a gray area. They aren’t held to that same evidentiary standard, and they aren’t permitted to claim they treat cognitive diseases. What they can say is that they support normal brain function. For a consumer, this means the evidence behind a supplement is almost always thinner and less rigorously tested than the evidence behind an approved medication.
Safety Considerations
The individual ingredients in NeuroQ are generally well tolerated. The most commonly reported side effects for supplements in this category are mild gastrointestinal discomfort, nausea, headache, and occasional dizziness. These tend to be short-lived and rarely require stopping the supplement.
The bigger concern is drug interactions. Ginkgo biloba, for instance, can interact with blood thinners and certain medications metabolized by the liver. Turmeric may also affect blood clotting. If you’re taking prescription medications, particularly anticoagulants, anti-seizure drugs, or blood pressure medications, it’s worth checking with a pharmacist before adding NeuroQ or any supplement containing these ingredients to your routine.
Because the FDA doesn’t test supplements before sale, there’s also the question of manufacturing quality. Some supplement companies voluntarily submit to third-party testing for purity and potency, which provides an extra layer of assurance that what’s on the label matches what’s in the capsule. Whether NeuroQ undergoes such testing is worth investigating before purchasing.